A carregar...
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial
IMPORTANCE: Based on a small retrospective study, rechallenge with cetuximab-based therapy for patients with KRAS wild-type metastatic colorectal cancer (mCRC) who were previously treated with the same anti–epidermal growth factor receptor–based regimen might be efficacious. Recent data suggest the...
Na minha lista:
| Publicado no: | JAMA Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Medical Association
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6439839/ https://ncbi.nlm.nih.gov/pubmed/30476968 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.5080 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|